Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280195 | 1.00 | TSHR (0.69) | TSHRLMNATRPA1TRPV1ALOX15 | |
| SCHEMBL8591050 | 0.89 | TSHR (0.71) | TSHRLMNATRPA1TRPV1ALOX15 | |
| SCHEMBL818273 | 0.83 | LMNA (0.46) | TSHRLMNATRPV1ALDH1A1TP53 | |
| SCHEMBL13041969 | 0.83 | LMNA (0.50) | TSHRLMNATRPV1CHRM3 | |
| SCHEMBL28867133 | 0.83 | TSHR (0.63) | TSHRLMNATRPA1TRPV1ALOX15 | |
| SCHEMBL13301247 | 0.83 | TSHR (0.77) | TSHRLMNATRPA1TRPV1ALOX15 | |
| SCHEMBL14626987 | 0.83 | TSHR (0.77) | TSHRLMNATRPA1TRPV1ALOX15 | |
| SCHEMBL8591960 | 0.82 | TSHR (0.71) | TSHRLMNATRPA1TRPV1ALOX15 | |
| Perillic Acid SCHEMBL8434974 | 0.81 | TSHR (1.00) | TSHRLMNATRPA1TRPV1ALOX15 | |
| Perillic Acid SCHEMBL19341660 | 0.81 | TSHR (1.00) | TSHRLMNATRPA1TRPV1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250249108-A1 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2025-08-07 | — | — | US | claimed |
| EP-4504211-A2 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2023196668-A2 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2023-10-12 | — | — | WO | claimed |
| CN-104945336-B | Perillic acid methyl esters nitrogen containing derivative and its preparation and application | 沈阳药科大学 | 2018-02-16 | — | — | CN | claimed |
| EP-0750497-A1 | USES OF PERILLYL ALCOHOL AND PERILLIC ACID METHYL ESTER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-01-02 | — | — | EP | claimed |
| US-5470877-A | Causing carcinoma regression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-11-28 | — | — | US | claimed |
| WO-1995024895-A1 | USES OF PERILLYL ALCOHOL AND PERILLIC ACID METHYL ESTER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-09-21 | — | — | WO | claimed |
| US-20250249108-A1 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4504211-A2 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196668-A2 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-104945336-B | Perillic acid methyl esters nitrogen containing derivative and its preparation and application | 沈阳药科大学 | 2018-02-16 | — | — | CN | disclosed |
| US-20170260121-A1 | COMPOUND, PROCESS FOR PREPARING A COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND METHOD FOR TREATING CANCER | FUNDAÇÃO OSWALDO CRUZ (BR) | 2017-09-14 | — | — | US | disclosed |
| EP-3184503-A1 | PERILLIC ACID DERIVATIVE, METHOD FOR PREPARING A PERILLIC ACID DERIVATIVE, PHARMACEUTICAL COMPOSITION, USE OF A PERILLIC ACID DERIVATIVE AND CANCER TREATMENT METHOD | Fundaçâo Oswaldo Cruz (BR) | 2017-06-28 | — | — | EP | disclosed |
| EP-0750497-A1 | USES OF PERILLYL ALCOHOL AND PERILLIC ACID METHYL ESTER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-01-02 | — | — | EP | disclosed |
| US-5470877-A | Causing carcinoma regression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-11-28 | — | — | US | disclosed |
| US-5470877-A | Causing carcinoma regression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-11-28 | — | — | US | disclosed |
| US-5470877-A | Causing carcinoma regression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1995024895-A1 | USES OF PERILLYL ALCOHOL AND PERILLIC ACID METHYL ESTER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-09-21 | — | — | WO | disclosed |
| WO-1995024895-A1 | USES OF PERILLYL ALCOHOL AND PERILLIC ACID METHYL ESTER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-09-21 | — | — | WO | disclosed |
| WO-1995024895-A1 | USES OF PERILLYL ALCOHOL AND PERILLIC ACID METHYL ESTER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260121-A1 | COMPOUND, PROCESS FOR PREPARING A COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND METHOD FOR TREATING CANCER | CA2, KCNMA1, KCNJ11 | TSHR 4626/4885LMNA 1681/4885TRPA1 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.